Open AccessDasatinib-induced diffuse alveolar hemorrhage
Author(s) -
Dhara Dave,
John Kimbugwe,
Randa Hazam,
Saria Tasnim,
Manish Patel
Publication year - 2021
Publication title -
the southwest respiratory and critical care chronicles
Language(s) - English
Resource type - Journals
ISSN - 2325-9205
DOI - 10.12746/swrccc.v9i41.897
Subject(s) - dasatinib , medicine , diffuse alveolar hemorrhage , pulmonary toxicity , tyrosine kinase inhibitor , myeloid leukemia , pleural effusion , diffuse alveolar damage , lung , gastroenterology , pathology , imatinib , cancer , acute respiratory distress
The BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid leukemia (CML). However, it is associated with pulmonary toxicities. Commonly reported dasatinib related pulmonary toxicities include pleural effusion, lung parenchymal abnormalities, and pulmonary hypertension. Diffuse alveolar hemorrhage (DAH) during treatment with dasatinib is very rare. To the best of our knowledge there are only two cases reported. Here we report a 57-year-old Caucasian woman who developed acute hypoxic respiratory failure while on dasatinib for treatment of CML. She was diagnosed with DAH suspected to be secondary to dasatinib, after other common etiologies were ruled out. There was full recovery after stopping dasatinib and treatment with corticosteroids.
Keywords: Dasatinib, pulmonary toxicity, diffuse alveolar hemorrhage, chronic myeloid leukemia